Paul Tudor Jones’s Akero Therapeutics AKRO Stock Holding History

Paul Tudor Jones’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,500	Closed	-$736K	–	3445
2025 Q3	$736K	Buy	15,500 +1,800	+13%	+$87.2K	﹤0.01%	2472
2025 Q2	$731K	Buy	13,700 +6,800	+99%	+$309K	﹤0.01%	2341
2025 Q1	$279K	Buy	+6,900	New	+$292K	﹤0.01%	2640

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Paul Tudor Jones's AKRO Position: Q4 2025 in Review

Paul Tudor Jones sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 51,356 shares — an estimated $2.44M sold.

Paul Tudor Jones first reported a position in AKRO in Q3 2022 and held it in 11 quarters. The position peaked at $2.44M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Paul Tudor Jones reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Paul Tudor Jones sold 51,356 Akero Therapeutics shares in Q4 2025, an estimated $2.44M.
Paul Tudor Jones first reported a position in Akero Therapeutics in Q3 2022 and held it in 11 quarters.
Paul Tudor Jones's Akero Therapeutics position peaked at $2.44M in Q3 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Tudor Investment Corp's 13F filing for Q4 2025, filed 17 Feb 2026.